In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Mirati Therapeutics, Inc.. Trade Record

NASDAQ:MRTX Mirati Therapeutics, Inc. stock gains 19.88% Exit Jun 4, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart MRTX May 8, 2018, priceSeries
About Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
98.57
Entry Date
May 8, 2018
Entry Price
33.25
Sell Date
Jun 4, 2018
Sell Price
39.86
Net Gain
19.88%
Hold Time
18 Trading Days